Shenzhen Hepalink Pharmaceutical Co Ltd (002399) — Financial Flexibility Index
Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has a Financial Flexibility Index of 0.09x as of September 2025. Free cash flow of CN¥413.04 Million (operating CF CN¥399.43 Million minus capex CN¥13.60 Million) represents 0% of total liabilities (CN¥4.70 Billion). Check Shenzhen Hepalink Pharmaceutical Co Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Shenzhen Hepalink Pharmaceutical Co Ltd Financial Flexibility Index (2006–2025)
Historical Financial Flexibility Index trend for Shenzhen Hepalink Pharmaceutical Co Ltd across 20 annual periods. For the full cash flow conversion analysis, see 002399 cash flow conversion.
Annual Financial Flexibility Index for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)
Year-by-year free cash flow to debt coverage for Shenzhen Hepalink Pharmaceutical Co Ltd. Explore Shenzhen Hepalink Pharmaceutical Co Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.40x | CN¥1.83 Billion | CN¥1.71 Billion | CN¥4.55 Billion | ▼ -13.6% |
| 2024 | 0.47x | CN¥2.40 Billion | CN¥2.19 Billion | CN¥5.14 Billion | ▲ +299.0% |
| 2023 | 0.12x | CN¥843.09 Million | CN¥398.22 Million | CN¥7.22 Billion | ▲ +283.9% |
| 2022 | -0.06x | CN¥-534.19 Million | CN¥-756.61 Million | CN¥8.41 Billion | ▼ -357.4% |
| 2021 | 0.02x | CN¥187.23 Million | CN¥-6.63 Million | CN¥7.58 Billion | ▼ -27.5% |
| 2020 | 0.03x | CN¥249.77 Million | CN¥37.28 Million | CN¥7.34 Billion | ▲ +96.7% |
| 2019 | 0.02x | CN¥134.47 Million | CN¥-227.60 Million | CN¥7.77 Billion | ▼ -89.3% |
| 2018 | 0.16x | CN¥1.20 Billion | CN¥667.87 Million | CN¥7.41 Billion | ▲ +428.5% |
| 2017 | 0.03x | CN¥169.01 Million | CN¥-407.12 Million | CN¥5.50 Billion | ▼ -79.0% |
| 2016 | 0.15x | CN¥705.61 Million | CN¥346.07 Million | CN¥4.83 Billion | ▼ -53.5% |
| 2015 | 0.31x | CN¥1.06 Billion | CN¥893.71 Million | CN¥3.38 Billion | ▼ -54.0% |
| 2014 | 0.68x | CN¥1.08 Billion | CN¥912.80 Million | CN¥1.58 Billion | ▼ -80.5% |
| 2013 | 3.51x | CN¥714.94 Million | CN¥420.97 Million | CN¥203.80 Million | ▲ +5.8% |
| 2012 | 3.32x | CN¥711.44 Million | CN¥473.89 Million | CN¥214.53 Million | ▼ -87.1% |
| 2011 | 25.67x | CN¥1.54 Billion | CN¥1.41 Billion | CN¥59.98 Million | ▲ +579.3% |
| 2010 | 3.78x | CN¥390.80 Million | CN¥354.86 Million | CN¥103.44 Million | ▲ +181.8% |
| 2009 | 1.34x | CN¥410.72 Million | CN¥355.81 Million | CN¥306.33 Million | ▲ +613.5% |
| 2008 | 0.19x | CN¥50.94 Million | CN¥40.13 Million | CN¥271.09 Million | ▼ -18.9% |
| 2007 | 0.23x | CN¥25.80 Million | CN¥13.85 Million | CN¥111.28 Million | ▼ -27.5% |
| 2006 | 0.32x | CN¥82.36 Million | CN¥71.66 Million | CN¥257.68 Million | — |